Replies to post #219819 on Biotech Values

[DewDiligence]

OXUR.BR -41% on phase-2 failure in DME:

https://www.globenewswire.com/news-release/2019/08/20/1903844/0/en/Oxurion-NV-Reports-Topline-Month-3-Results-of-Phase-2a-Study-Evaluating-THR-317-anti-PLGF-in-Combination-with-Ranibizumab-for-DME.html

The "name change" rule would've worked in this instance.